Home/Transneural Therapeutics/David Frawley

DF

David Frawley

Strategic Advisor

Transneural Therapeutics

Therapeutic Areas

Psychiatry Neurology

Transneural Therapeutics Pipeline

Drug	Indication	Phase
TN-001	Neuropsychiatric Disorders (e.g., MDD, PTSD)	Pre-clinical
Undisclosed Program 2	Neuropsychiatric Disorders	Pre-clinical
Undisclosed Program 3	Neuropsychiatric Disorders	Pre-clinical

Leadership Team at Transneural Therapeutics

Charmaine Lykins, MBA

Chief Executive Officer

Mark A. Demitrack, MD

Chief Research and Development Officer

View full Transneural Therapeutics profile